Cryoport, Experiences Significant Increase in Short Interest

January 6, 2024

☀️Trending News

Cryoport ($NASDAQ:CYRX), Inc. (NASDAQ: CYRX) recently experienced a significant increase in short interest. Cryoport, Inc. is a leading provider of cold chain logistics solutions for life sciences and biotechnology-related companies. The company specializes in the management, storage and transportation of temperature-sensitive life sciences products. Cryoport utilizes advanced packaging technologies to manage its customers’ valuable payloads in a secure and reliable cold chain environment.

Cryoport’s solutions are used by major pharmaceutical, biotechnology, animal health, and diagnostic laboratories across the world. With offices in the United States, Europe, and Asia, Cryoport is well-positioned to meet the needs of its global customer base.

Price History

The stock opened at $15.2 and closed at $15.4, representing an increase of 2.2% from the prior closing price of $15.1. This increase in short interest is likely due to the company’s recent announcement of a partnership with a major pharmaceutical manufacturer. The partnership will allow Cryoport to expand its services into the biopharma and life science industries, thus positioning them for future growth. Investors may be betting on the success of this new partnership and the potential of Cryoport’s services to drive their stock price. Live Quote…

About the Company

  • Cryoport_Experiences_Significant_Increase_in_Short_Interest”>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Cryoport. More…

    Total Revenues Net Income Net Margin
    236.35 -54.63 -25.2%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Cryoport. More…

    Operations Investing Financing
    0.41 57.93 -28.98
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Cryoport. More…

    Total Assets Total Liabilities Book Value Per Share
    1k 463.13 10.98
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Cryoport are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    81.4% -16.0%
    FCF Margin ROE ROA
    -17.2% -4.4% -2.4%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has conducted a financial analysis of CRYOPORT‘s performance, using Star Chart. According to this analysis, CRYOPORT has an intermediate health score of 4/10 in terms of its cashflows and debt, meaning that it might be able to pay off that debt and fund future operations. The company is strong in terms of asset and growth but weak in terms of dividend and profitability, which is why we have classified it as a ‘rhino’; a type of company that has achieved moderate revenue or earnings growth. Given its financial performance, what type of investors may be interested in such a company? Such investors may be those who are looking for long-term investments with potential for capital gains in the future or those who understand the importance of investing in growing companies, regardless of their current dividend or profitability metrics. CRYOPORT may also interest more risk-averse investors who wish to invest in a company with intermediate health score and the potential for future returns. More…

  • Star Chart Analysis
  • Valuation Analysis




  • Peers

    In the logistics and transportation industry, there is intense competition among companies to provide the most efficient and cost-effective services. This is especially true for companies specializing in cryogenic transportation, where time and temperature sensitive shipments are the norm. In this arena, CryoPort Inc. has been a leader, innovating and investing in cutting-edge technology to stay ahead of the competition. Some of its main competitors include Shenzhen Prolto Supply Chain Management Co Ltd, Xinjiang Tianshun Supply Chain Co Ltd, and BEST Inc. While each company has its own strengths and weaknesses, CryoPort has consistently remained at the forefront of the industry, providing superior service and value to its customers.

    – Shenzhen Prolto Supply Chain Management Co Ltd ($SZSE:002769)

    Shenzhen Prolto Supply Chain Management Co Ltd has a market cap of 3.23B as of 2022, and a Return on Equity of 2.47%. The company is engaged in the business of providing supply chain management services. It offers services such as logistics, transportation, warehousing, and distribution. The company has a network of over 1,000 warehouses in China.

    – Xinjiang Tianshun Supply Chain Co Ltd ($SZSE:002800)

    Xinjiang Tianshun Supply Chain Co Ltd is a Chinese company that operates in the logistics and supply chain management industry. The company has a market capitalization of 2.2 billion US dollars as of 2022 and a return on equity of 6.85 percent. Xinjiang Tianshun Supply Chain Co Ltd is headquartered in the city of Urumqi in the Xinjiang Uyghur Autonomous Region of China. The company was founded in the year 2006.

    – BEST Inc ($NYSE:BEST)

    BEST Inc. is a leading express delivery and logistics company in China, with a market cap of $49.1 million as of 2022. The company has a return on equity of -60.92%. BEST Inc. provides express delivery, warehousing, and logistics services in China. The company operates a network of over 30,000 stores and more than 200 warehouses across China.

    Summary

    CRYOPORT, Inc., a leading provider of cold chain logistics solutions for the life sciences industry, has seen a significant increase in short interest. This suggests that many investors are taking a bearish view of the company and its prospects. Analysts have noted that CRYOPORT’s business model has been able to capitalize on the growing trend of online delivery services and the need for temperature-controlled solutions for biopharmaceutical products.

    Despite this, many investors remain concerned about the company’s ability to generate long-term profits and maintain its lead in the industry. As such, investors should closely monitor the company’s financial performance and any potential roadblocks in its path.

    Recent Posts

    Leave a Comment